KRAS and cancer: Furthermore, we demonstrated that the limited in vivo efficacy of CDK9i in KRAS‐mutant cancers can be attributed not only to the activated pro‐survival signaling in tumor cells but also to the immunosuppressive TME orchestrated by the complement system.